Existing research supports the role of immunonutrition from several studies with varying nutrition supplements which have resulted in decreased complications following surgery. The primary objective of S1600 will be to compare the impact of consuming perioperative specialized immunemodulating drinks (SIM, Impact Advanced Recovery®, Nestlé) to oral nutrition supplement control drinks (ONS, Oral Nutrition Control, Nestlé) on post-operative complications (any vs. none) within 30 days after scheduled radical cystectomy. Secondary outcomes will be assessed and also include evaluation of consuming SIM vs. ONS on immune response, cytokines, amino acids, and fatty acids. A total of 200 patients will be randomized and the study will address the question of whether implementation of a high-yield, low-risk, low-cost strategy may improve outcomes in patients undergoing radical cystectomy.
Dr. Hamilton-Reeves also reviewed several other monitoring applications available to capture study components and other trials assessing impact of weight management, carbohydrate loading, anemia, and microbiome with surgical outcomes. At her institution, they are opening this pivotal S1600 trial and strongly encourage other institutions to do so as well in order to reduce the non-negligible morbidity and mortality associated with radical cystectomy.
Presented by: Jill Hamilton-Reeves, PhD, RD, CSO, Associate Professor, Department of Dietetics and Nutrition, University of Kansas, Kansas City, Kansas
Written by: Stephen B. Williams, MD, Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, Texas at the 7th ERAS World Congress, Liverpool, UK, 1-3 May 2019.